Vantage logo

Finding the next Prevail

An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.

Vantage logo

Finding the next Vertex

Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.